Clinical outcomes of MyoRing implantation in keratoconic eyes by using the Femtosecond laser technology.

To assess the outcomes of the insertion of the MyoRing (DIOPTEX, GMBH, Linz, Austria) by applying the Femtosecond Laser Technology (FLT) method in eyes that have keratoconus problem. A prospective, nonrandomized, clinical examination was managed. 27 eyes of 15 subjects with stable keratoconus (6 females and 9 males), with lifetimes differing from 14 to 49 years were involved. All subjects have problems about decreased fine-accurate ocular awareness, lens intolerantness or trouble, and also the middle corneal height larger than 350 micrometers. MyoRing additions of about 320 micrometers into height and 2.5 mm into radius were inserted in each subject inside an Intrastromal Corneal Pocket using(ICP) formed with applying FLT. Ocular, refractive errors, corneal shape, and pachymetry changes were assessed throughout a 6-months follow-up period. The average UDVA (uncorrected distance visual acuity) notably increased originating at 1.73 ± 0.53 LogMAR preoperationally to 0.54 ± 0.40 LogMAR post-operationally. The average CDVA (corrected distance ocular awareness) notably increased from 0.59 ± 0.47 LogMAR preoperationally to 0.27 ± 0.16 LogMAR post-operationally. The change in the average UDVA and CDVA was analytically meaningful (P< 0.000). The average reduction in the average keratometry from preoperational to 26 weeks post operational was -6.41 ± 3.62 D. This change was analytically meaningful (P< 0.000). The average lowest and highest keratometry amounts were similarly analytically notable at shorter than 26 weeks preoperatively. A notable increase in UDVA and CDVA was observed 26 weeks following the operation, that was compatible with the notable decrease in sphere and cylinder. Moreover, a notable corneal straightening with an average amount of -6.41 ± 3.62 diopters (D) was determined. MyoRing implantation employing FLT would be a harmless, effective, and predictable method to treat selected subjects of keratoconus, being a helpful choice for the therapy of keratoconus.